Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS001 in advanced solid tumors
NCT02836834Phase 1Unknown
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Aug 2016
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of toripalimab in solid tumor, lymphoma, soft tissue sarcoma (STS) and 1 more (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Safety and Tolerability (Adverse Events) at 154 days. Status: unknown.
02
Drugs
toripalimab
03
Conditions
solid tumorlymphomasoft tissue sarcoma (STS)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02836834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836834.